Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.184 - carbonyl reductase (NADPH)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma of Lung
Human carbonyl reductase 1 is an S-nitrosoglutathione reductase.
Brain Injuries
Carbonyl Reductase 1 Attenuates Ischemic Brain Injury by Reducing Oxidative Stress and Neuroinflammation.
Breast Neoplasms
Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Carcinogenesis
Association between CBR1 polymorphisms and NSCLC in the Chinese population.
Carcinoma
Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Decreased carbonyl reductase 1 expression promotes tumor growth via epithelial mesenchymal transition in uterine cervical squamous cell carcinomas.
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma.
Carcinoma, Hepatocellular
Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Carcinoma, Squamous Cell
Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Decreased carbonyl reductase 1 expression promotes tumor growth via epithelial mesenchymal transition in uterine cervical squamous cell carcinomas.
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Cardiotoxicity
Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma.
DNA sequence variants in the carbonyl reductase 1 (cbr1) gene in seven breeds of Canis lupus familiaris.
EXPRESSION OF THE ANTHRACYCLINE METABOLIZING ENZYME CARBONYL REDUCTASE 1 (CBR1) IN HEARTS FROM DONORS WITH DOWN SYNDROME.
Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment.
Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1.
Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1.
Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Dehydration
An unusual dehydratase acting on glycerate and a ketoreducatse stereoselectively reducing ?-ketone in polyketide starter unit biosynthesis.
Inhibition of mammalian fatty acid synthetase activity by NADP involves decreased mobility of the 4'-phosphopantetheine prosthetic group.
Reconstitution of a Type II Polyketide Synthase that Catalyzes Polyene Formation.
Stereospecificity of the dehydratase domain of the erythromycin polyketide synthase.
Diabetes Mellitus, Type 2
Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.
Down Syndrome
EXPRESSION OF THE ANTHRACYCLINE METABOLIZING ENZYME CARBONYL REDUCTASE 1 (CBR1) IN HEARTS FROM DONORS WITH DOWN SYNDROME.
Drug Resistant Epilepsy
CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.
Gastrointestinal Neoplasms
Up-Regulation of Carbonyl Reductase 1 Renders Development of Doxorubicin Resistance in Human Gastrointestinal Cancers.
Heart Failure
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Insulin Resistance
Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.
Keloid
Upregulation of the NNP-1 (novel nuclear protein-1, D21S2056E) gene in keloid tissue determined by cDNA microarray and in situ hybridization.
Kidney Failure, Chronic
Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease.
Leiomyosarcoma
Overexpression of carbonyl reductase 1 inhibits malignant behaviors and epithelial mesenchymal transition by suppressing TGF-? signaling in uterine leiomyosarcoma cells.
Leukemia
Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide.
Correction: Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide.
Leukemia, Myeloid, Acute
Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
Liver Diseases
Identification and Analysis of the Tegument Protein and Excretory-Secretory Products of the Carcinogenic Liver Fluke Clonorchis sinensis.
Lung Neoplasms
Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells - Involvement of carbonyl reductase 1.
Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene.
Malformations of Cortical Development
CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.
Neoplasm Metastasis
Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis.
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.
Neoplasms
Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century.
Association between CBR1 polymorphisms and NSCLC in the Chinese population.
Carbonyl Reductase 3 (CBR3) Mediates 9-cis-Retinoic Acid-Induced Cytostatis and is a Potential Prognostic Marker for Oral Malignancy.
Decreased carbonyl reductase 1 expression promotes tumor growth via epithelial mesenchymal transition in uterine cervical squamous cell carcinomas.
Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation.
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Identification and Analysis of the Tegument Protein and Excretory-Secretory Products of the Carcinogenic Liver Fluke Clonorchis sinensis.
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling.
Overexpression of carbonyl reductase 1 inhibits malignant behaviors and epithelial mesenchymal transition by suppressing TGF-? signaling in uterine leiomyosarcoma cells.
Regulation of Human Carbonyl Reductase 3 (CBR3; SDR21C2) Expression by Nrf2 in Cultured Cancer Cells.
The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.
Neuroinflammatory Diseases
Carbonyl Reductase 1 Attenuates Ischemic Brain Injury by Reducing Oxidative Stress and Neuroinflammation.
Obesity
Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice.
Carbonyl reductase 1 catalyzes 20?-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity.
Ovarian Neoplasms
Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation.
Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models.
Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.
Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling.
Prostatic Neoplasms
Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Reperfusion Injury
Upregulation of Carbonyl Reductase 1 by Nrf2 as a Potential Therapeutic Intervention for Ischemia/ Reperfusion Injury during Liver Transplantation.
Squamous Cell Carcinoma of Head and Neck
Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Inhibition of Carbonyl Reductase 1 Enhances Metastasis of Head and Neck Squamous Cell Carcinoma through ?-catenin-Mediated Epithelial-Mesenchymal Transition.
Low carbonyl reductase 1 expression is associated with poor prognosis in patients with oral squamous cell carcinoma.
Tuberculosis
Crystal structure of FabG4 from Mycobacterium tuberculosis reveals the importance of C-terminal residues in ketoreductase activity.
F420H2 Is Required for Phthiocerol Dimycocerosate Synthesis in Mycobacteria.
Tuberous Sclerosis
CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic developmental pathologies.